News & Events
September 25, 2018
UA Colleges of Law and Pharmacy, Critical Path Institute, Launch Graduate Certificate Program in Regulatory ScienceDesigned for graduate students and working professionals, the certificate program provides specialized training in navigating the path from research to bringing medical products to market. TUCSON, Ariz., September 25, 2018 — The University of Arizona and the Critical Path Institute have launched a new online graduate certificate program designed to equip students and working......
September 17, 2018
Critical Path Institute and SIGNATOPE GmbH Team Up to Advance Research on Biomarkers for Drug-induced Organ InjuriesTUCSON, Ariz. and REUTLINGEN, September 17, 2018 — Critical Path Institute’s Predictive Safety Testing Consortium (PSTC) and SIGNATOPE GmbH are excited to announce a new project, joining efforts on analyzing and qualifying promising protein safety biomarkers in mouse, rat, dog, monkey, and human. The work is expected to increase understanding of drug-induced toxicities......
September 6, 2018
Doris Duke Charitable Foundation Awards Grant to Critical Path Institute to Advance Therapies for Sickle Cell DiseaseContacts: Kissy Black, Critical Path Institute [email protected], 615.298.1144 Kristin Roth-Schrefer, Communications Director [email protected], 212.974.7003 Nina Chung, Communications Associate [email protected], 212.974.7006 Critical Path Institute (C-Path) Will Plan a Consortium of Stakeholders Focused on Developing Therapies for Sickle Cell Disease NEW YORK, September 6, 2018 — In a continuing effort to spur advancements in treating......
July 26, 2018
First-ever biomarker qualified for Parkinson’s is a vital step toward improved clinical trialsFOR IMMEDIATE RELEASE Contact: Kissy Black 615.298.1144 [email protected] Tucson, AZ — July 26, 2018 – The Critical Path Institute’s (C-Path) Critical Path for Parkinson’s Consortium (CPP), in partnership with Parkinson’s UK, announces that the European Medicines Agency (EMA) has issued a positive qualification opinion on an imaging test (biomarker) as a tool to enrich......
May 7, 2018
C-Path Receives COA Qualification from FDA for the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ)TUCSON, Ariz. – May 7, 2018 — Critical Path Institute‘s (C-Path) Patient-Reported Outcome (PRO) Consortium announces its second clinical outcome assessment (COA) qualification from the US Food and Drug Administration (FDA). The qualification of the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) for exploratory use represents another major milestone for the PRO Consortium and, specifically,......